Exchange: NASDAQ·Updated 04:34 PM EDT
News
all
press releases
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
More News
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.
Zacks
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.
Zacks
What to Know About This Fund's New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
What to Know About This Fund's New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing...
Yahoo! Finance: News
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.
Zacks
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been given a consensus recommendation of "Buy" by the eighteen analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a bu...
MarketBeat
Xenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on Monday
Xenon Pharmaceuticals (NASDAQ:XENE) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...
MarketBeat
Jennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE
Jennison Associates LLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.8% during the fourth quarter, according to the company in its most recent...
MarketBeat
Pictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENE
Pictet Asset Management Holding SA decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 50.4% in the fourth quarter, according to its most recent Form 13F...
MarketBeat

Advertisement|Remove ads.